{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:21:11Z","timestamp":1791307271395,"version":"4.3.1"},"reference-count":61,"publisher":"Society of Nuclear Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Nucl. Med.\n                Technol."],"accepted":{"date-parts":[[2026,3,17]]},"published-print":{"date-parts":[[2026,6]]},"DOI":"10.2967\/jnmt.125.271979","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:50:11Z","timestamp":1777391411000},"page":"136-143","source":"Crossref","is-referenced-by-count":4,"title":["Prostate Cancer, Part 2: PSMA and Beyond"],"prefix":"10.2967","volume":"54","author":[{"given":"Geoffrey M.","family":"Currie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Rohren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"2026060306101359000_54.2.136.1","doi-asserted-by":"publisher","DOI":"10.2967\/jnmt.125.271978"},{"key":"2026060306101359000_54.2.136.2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.semradonc.2025.04.003","article-title":"Radiopharmaceuticals in prostate cancer: general considerations and utility in combination with EBRT","volume":"35","author":"Civan","year":"2025","journal-title":"Semin Radiat Oncol."},{"key":"2026060306101359000_54.2.136.3","doi-asserted-by":"crossref","first-page":"17588359231208960","DOI":"10.1177\/17588359231208960","article-title":"Current role of PSMA-PET imaging in the clinical management of prostate cancer","volume":"15","author":"Georgakopoulos","year":"2023","journal-title":"Ther Adv Med Oncol."},{"key":"2026060306101359000_54.2.136.4","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3390\/ph17111458","article-title":"Different PSMA radiopharmaceuticals: a comparative study of [18F]F-PSMA-1007, [18F]F-JK-PSMA-7, and [99mTc]Tc-PSMA-I&S in the skeletal system","volume":"17","author":"Mik\u00f3","year":"2024","journal-title":"Pharmaceuticals (Basel)."},{"key":"2026060306101359000_54.2.136.5","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20172050"},{"key":"2026060306101359000_54.2.136.6","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171052"},{"key":"2026060306101359000_54.2.136.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.203877"},{"key":"2026060306101359000_54.2.136.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101450"},{"key":"2026060306101359000_54.2.136.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2013.09.003"},{"key":"2026060306101359000_54.2.136.10","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1053\/j.semnuclmed.2025.01.007","article-title":"Sharpening the blade of precision theranostics","volume":"55","author":"Currie","year":"2025","journal-title":"Semin Nucl Med."},{"key":"2026060306101359000_54.2.136.11","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/jmrs.836","article-title":"Molecular theranostics: principles, challenges and controversies","volume":"72","author":"Currie","year":"2025","journal-title":"J Med Radiat Sci."},{"key":"2026060306101359000_54.2.136.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026060306101359000_54.2.136.13","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14876"},{"key":"2026060306101359000_54.2.136.14","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233460"},{"key":"2026060306101359000_54.2.136.15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.191023"},{"key":"2026060306101359000_54.2.136.16","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30080529"},{"key":"2026060306101359000_54.2.136.17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00259-025-07390-0","article-title":"Targeted alpha therapy: a comprehensive analysis of the biological effects from \u201clocal-regional-systemic\u201d dimensions","volume":"53","author":"Song","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026060306101359000_54.2.136.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.11.013"},{"key":"2026060306101359000_54.2.136.19","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.7150\/thno.96403","article-title":"Actinium-225 targeted alpha particle therapy for prostate cancer","volume":"14","author":"Bidkar","year":"2024","journal-title":"Theranostics."},{"key":"2026060306101359000_54.2.136.20","doi-asserted-by":"publisher","DOI":"10.2174\/1874471011666180502104524"},{"key":"2026060306101359000_54.2.136.21","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s13139-023-00804-7","article-title":"161Tb-PSMA unleashed: a promising new player in the theranostics of prostate cancer","volume":"57","author":"Al-Ibraheem","year":"2023","journal-title":"Nucl Med Mol Imaging."},{"key":"2026060306101359000_54.2.136.22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40658-023-00589-w","article-title":"Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection","volume":"10","author":"Verburg","year":"2023","journal-title":"EJNMMI Phys."},{"key":"2026060306101359000_54.2.136.23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267650"},{"key":"2026060306101359000_54.2.136.24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13550-019-0538-1","article-title":"Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET\/CT imaging of prostate cancer","volume":"9","author":"M\u00fcller","year":"2019","journal-title":"EJNMMI Res."},{"key":"2026060306101359000_54.2.136.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinorgbio.2010.11.003"},{"key":"2026060306101359000_54.2.136.26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s41181-021-00131-2","article-title":"Production of scandium radionuclides for theranostic applications: towards standardization of quality requirements","volume":"6","author":"Mikolajczak","year":"2021","journal-title":"EJNMMI Radiopharm Chem."},{"key":"2026060306101359000_54.2.136.27","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20180074"},{"key":"2026060306101359000_54.2.136.28","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.3390\/molecules28166041","article-title":"Accelerator-based production of scandium radioisotopes for applications in prostate cancer: toward building a pipeline for rapid development of novel theranostics","volume":"28","author":"Meier","year":"2023","journal-title":"Molecules."},{"key":"2026060306101359000_54.2.136.29","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1053\/j.semnuclmed.2025.01.005","article-title":"Potential for technetium and rhenium theranostics","volume":"55","author":"Currie","year":"2025","journal-title":"Semin Nucl Med."},{"key":"2026060306101359000_54.2.136.30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2174\/1874471011205030228","article-title":"Rhenium-188: availability from the 188W\/188Re generator and status of current applications","volume":"5","author":"Pillai","year":"2012","journal-title":"Curr Radiopharm."},{"key":"2026060306101359000_54.2.136.31","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267450"},{"key":"2026060306101359000_54.2.136.32","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264944"},{"key":"2026060306101359000_54.2.136.33","doi-asserted-by":"publisher","DOI":"10.7150\/thno.48107"},{"key":"2026060306101359000_54.2.136.34","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1021\/acs.molpharmaceut.4c00066","article-title":"Radiopharmaceuticals targeting gastrin-releasing peptide receptor for diagnosis and therapy of prostate cancer","volume":"21","author":"Zou","year":"2024","journal-title":"Mol Pharmaceutics."},{"key":"2026060306101359000_54.2.136.35","doi-asserted-by":"crossref","first-page":"10061","DOI":"10.3390\/ijms231710061","article-title":"PET probes for preclinical imaging of GRPR-positive prostate cancer: comparative preclinical study of [68Ga]Ga-NODAGA-AMBA and [44Sc]Sc-NODAGA-AMBA","volume":"23","author":"K\u00e1lm\u00e1n-Szab\u00f3","year":"2022","journal-title":"Int J Mol Sci."},{"key":"2026060306101359000_54.2.136.36","first-page":"1144","article-title":"177Lu-AMBA: synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer","volume":"47","author":"Lantry","year":"2006","journal-title":"J Nucl Med."},{"key":"2026060306101359000_54.2.136.37","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.257758"},{"key":"2026060306101359000_54.2.136.38","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11307-017-1151-1","article-title":"Prostate cancer theranostics targeting gastrin-releasing peptide receptors","volume":"20","author":"Baratto","year":"2018","journal-title":"Mol Imaging Biol."},{"key":"2026060306101359000_54.2.136.39","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(24)00069-X","article-title":"68Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2\/3 imaging trial","volume":"25","author":"Duan","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026060306101359000_54.2.136.40","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.107.048009"},{"key":"2026060306101359000_54.2.136.41","doi-asserted-by":"crossref","first-page":"28151","DOI":"10.18632\/oncotarget.8611","article-title":"Non-invasive assessment of inter-and intrapatient variability of integrin expression in metastasized prostate cancer by PET","volume":"7","author":"Beer","year":"2016","journal-title":"Oncotarget."},{"key":"2026060306101359000_54.2.136.42","doi-asserted-by":"crossref","first-page":"e6800","DOI":"10.1002\/cam4.6800","article-title":"RGD peptide in cancer targeting: benefits, challenges, solutions, and possible integrin-RGD interactions","volume":"13","author":"Javid","year":"2024","journal-title":"Cancer Med."},{"key":"2026060306101359000_54.2.136.43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020070"},{"key":"2026060306101359000_54.2.136.44","doi-asserted-by":"crossref","first-page":"37137","DOI":"10.2174\/1568009614666140403123452","article-title":"PET imaging with [68Ga]NOTA-RGD for prostate cancer: a comparative study with [18F]fluorodeoxyglucose and [18F]fluoroethylcholine","volume":"14","author":"Israel","year":"2014","journal-title":"Curr Cancer Drug Targets."},{"key":"2026060306101359000_54.2.136.45","doi-asserted-by":"publisher","DOI":"10.7150\/thno.13242"},{"key":"2026060306101359000_54.2.136.46","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.3390\/jcm14165628","article-title":"Bispecific radioligands (BRLs): two is better than one","volume":"14","author":"Bentivoglio","year":"2025","journal-title":"J Clin Med."},{"key":"2026060306101359000_54.2.136.47","doi-asserted-by":"crossref","first-page":"1184309","DOI":"10.3389\/fnume.2023.1184309","article-title":"Radiolabeled iron oxide nanoparticles functionalized with PSMA\/BN ligands for dual-targeting of prostate cancer","volume":"3","author":"Bajwa","year":"2023","journal-title":"Front Nucl Med."},{"key":"2026060306101359000_54.2.136.48","doi-asserted-by":"publisher","DOI":"10.1021\/jm801285t"},{"key":"2026060306101359000_54.2.136.49","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.177048"},{"key":"2026060306101359000_54.2.136.50","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1021\/acsmedchemlett.4c00324","article-title":"Synthesis and preclinical evaluation of a bispecific PSMA-617\/RM2 heterodimer targeting prostate cancer","volume":"15","author":"Liolios","year":"2024","journal-title":"ACS Med Chem Lett."},{"key":"2026060306101359000_54.2.136.51","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s10967-018-6285-3","article-title":"Preparation and preclinical evaluation of 68Ga-iPSMA-BN as a potential heterodimeric radiotracer for PET-imaging of prostate cancer","volume":"318","author":"Mendoza-Figueroa","year":"2018","journal-title":"J Radioanal Nucl Chem."},{"key":"2026060306101359000_54.2.136.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2014.01.001"},{"key":"2026060306101359000_54.2.136.53","doi-asserted-by":"crossref","first-page":"108364","DOI":"10.1016\/j.nucmedbio.2023.108364","article-title":"Integrin \u03b1v\u03b23 and EGFR dual-targeted [64Cu]Cu-NOTA-RGD-GE11 heterodimer for PET imaging in pancreatic cancer mouse model","volume":"124\u2013125","author":"Li","year":"2023","journal-title":"Nucl Med Biol."},{"key":"2026060306101359000_54.2.136.54","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265383"},{"key":"2026060306101359000_54.2.136.55","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s00259-023-06587-5","article-title":"A comparison of [18F]AlF- and 68Ga-labeled dual targeting heterodimer FAPI-RGD in malignant tumor: preclinical evaluation and pilot clinical PET\/CT imaging","volume":"51","author":"Liu","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026060306101359000_54.2.136.56","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3390\/molecules28031088","article-title":"Synthesis and preclinical evaluation of three novel 68Ga-labeled bispecific PSMA\/FAP-targeting tracers for prostate cancer imaging","volume":"28","author":"Verena","year":"2023","journal-title":"Molecules."},{"key":"2026060306101359000_54.2.136.57","doi-asserted-by":"crossref","first-page":"6476","DOI":"10.1039\/D4QI01503G","article-title":"Development and biological evaluation of PSMA\/FAP dual targeting radiotracers for prostate cancer imaging","volume":"11","author":"Hou","year":"2024","journal-title":"Inorg Chem Front."},{"key":"2026060306101359000_54.2.136.58","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000000966"},{"key":"2026060306101359000_54.2.136.59","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s10967-017-5555-9","article-title":"Preparation and in\u00a0vitro evaluation of 177Lu-iPSMA-RGD as a new heterobivalent radiopharmaceutical","volume":"314","author":"Escudero-Castellanos","year":"2017","journal-title":"J Radioanal Nucl Chem."},{"key":"2026060306101359000_54.2.136.60","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/MNM.0b013e328362d2b6","article-title":"177Lu-labeled RGD-BBN heterodimeric peptide for targeting prostate carcinoma","volume":"34","author":"Jiang","year":"2013","journal-title":"Nucl Med Commun."},{"key":"2026060306101359000_54.2.136.61","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1021\/acs.jmedchem.0c01785","article-title":"Development of heterobivalent theranostic probes having high affinity\/selectivity for the GRPR\/PSMA","volume":"64","author":"Bandari","year":"2021","journal-title":"J Med Chem."}],"container-title":["Journal of Nuclear Medicine Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnmt.125.271979","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:10:41Z","timestamp":1780492241000},"score":1,"resource":{"primary":{"URL":"http:\/\/tech.snmjournals.org\/lookup\/doi\/10.2967\/jnmt.125.271979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":61,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6,3]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.2967\/jnmt.125.271979"],"URL":"https:\/\/doi.org\/10.2967\/jnmt.125.271979","relation":{},"ISSN":["0091-4916","1535-5675"],"issn-type":[{"value":"0091-4916","type":"print"},{"value":"1535-5675","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]}}}